NATALEE

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial

Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia[...]

By sjmartinez • October 24, 2024

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versusendocrine therapy alone in patients with HR+/HER2- early breast cancer

Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy[...]

By sjmartinez • June 6, 2023